Carmel Pharma

| | | | | |

Carmel Pharma AB

	Market PhaSeal is today a global product established in many countries around the world. Click here to learn more...
	Vision & Mission Our vision is to remain the world leader in closed drug transfer systems. Click here to learn more...
	Investor Relations Annual Reports, Members of the Board, Executive Management.

Investor Relations

Reports

Members of the Board

Executive Management

Carmel Update

Press release on unaudited annual earnings 2009

• Income for the period amounted to KSEK 284,047 (230,868)

• The consolidated earnings after tax amounted to KSEK 22,670 (16,762)

• Earnings per share before dilution were SEK 2.86 (2.11) for the period

• Available liquid funds* KSEK 32,777 (28,241)

• Continued investments for growth in key markets

• New products were launched during the year

Download